Making LDL Matter Again: Addressing Clinical, Patient, and Payer Barriers in ASCVD Management

EP. 1: Understanding the Current State of LDL-C Goal Attainment and Barriers to Adequate Control in Hyperlipidemia

ByNihar Desai, MD, MPH,Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC,Steven Kheloussi, PharmD, MBA, FAMCP,Joseph Saseen, PharmD, BCPS, BCACP, CLS

October 31st 2025

Panelists discuss how: LDL-C control remains a national crisis, with many patients not on therapy or failing to reach target levels despite the availability of effective treatments.

EP. 2: Challenges with Undertreatment in Hyperlipidemia and Opportunities to Address this Gap

ByNihar Desai, MD, MPH,Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC,Steven Kheloussi, PharmD, MBA, FAMCP,Joseph Saseen, PharmD, BCPS, BCACP, CLS

October 31st 2025

Panelists discuss how: clinical inertia, patient apathy, and the asymptomatic nature of high cholesterol all contribute to undertreatment and poor outcomes.

Making LDL Matter Again: Addressing Clinical, Patient, and Payer Barriers in ASCVD Management

EP. 1: Understanding the Current State of LDL-C Goal Attainment and Barriers to Adequate Control in Hyperlipidemia

EP. 2: Challenges with Undertreatment in Hyperlipidemia and Opportunities to Address this Gap

Trending on AJMC

5 Consequences If ACA Premium Subsidies End in 2026

Raludotatug Deruxtecan Demonstrates Promising Efficacy, Safety in Platinum-Resistant Ovarian Cancer

Jury Still Out on Testosterone Benefit to Menopause

Stereotactic Body Radiation Therapy Equally Effective as Surgery in Stage I NSCLC

Medicaid Coverage Associated With Employment Gains